Tarsus Pharmaceuticals, Inc.
General ticker "TARS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.0B (TTM average)
Tarsus Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 48.6%.
Estimated limits based on current volatility of 2.0%: low 73.58$, high 76.52$
Factors to consider:
- Total employees count: 323 (+32.4%) as of 2024
- Top business risk factors: Regulatory and compliance, Operational and conduct risks, Limited product diversification, Disaster recovery and infrastructure issues, Transition to commercialization
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [55.91$, 103.55$]
- 2026-12-31 to 2027-12-31 estimated range: [46.88$, 90.29$]
Financial Metrics affecting the TARS estimates:
- Negative: with PPE of -50.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.37 <= 0.01
- Positive: 42.68 < Shareholder equity ratio, % of 61.09 <= 64.29
- Positive: Inventory ratio change, % of -0.45 <= 0
- Positive: Interest expense per share per price, % of 0.26 <= 0.73
Short-term TARS quotes
Long-term TARS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $17.45MM | $182.95MM | $451.36MM |
| Operating Expenses | $160.60MM | $303.52MM | $522.33MM |
| Operating Income | $-143.16MM | $-120.57MM | $-70.97MM |
| Non-Operating Income | $7.26MM | $5.01MM | $6.61MM |
| Interest Expense | $3.35MM | $7.85MM | $8.94MM |
| R&D Expense | $50.31MM | $53.39MM | $64.32MM |
| Income(Loss) | $-135.89MM | $-115.55MM | $-64.36MM |
| Taxes | $0.00MM | $0.00MM | $2.06MM |
| Profit(Loss)* | $-135.89MM | $-115.55MM | $-66.42MM |
| Stockholders Equity | $196.99MM | $224.53MM | $343.43MM |
| Inventory | $3.11MM | $2.62MM | $4.37MM |
| Assets | $265.49MM | $376.99MM | $562.16MM |
| Operating Cash Flow | $-117.49MM | $-83.03MM | $-12.45MM |
| Capital expenditure | $5.50MM | $1.57MM | $9.86MM |
| Investing Cash Flow | $140.60MM | $-199.19MM | $-42.12MM |
| Financing Cash Flow | $130.18MM | $154.66MM | $143.39MM |
| Earnings Per Share** | $-4.62 | $-3.07 | $-1.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.